Latest Ratios: P/E Ratio -1.6x · EV/EBITDA N/A · ROE -2175.0%. (2019–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $17M | $20M | $22M | $11M | $14M | $27M | — | — |
| Enterprise Value | $17M | $20M | $19M | $8M | $11M | $17M | — | — |
| P/E Ratio → | -1.58 | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — |
| P/B Ratio | — | — | 8.64 | — | 2.50 | 2.97 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -2175.0% | -2175.0% | -2478.2% | -523.7% | -168.8% | -83.6% | -358.7% | -133.7% |
| ROA | -397.1% | -397.1% | -263.1% | -185.5% | -128.9% | -66.2% | -326.2% | -128.5% |
| ROIC | — | — | — | — | -987.8% | — | — | — |
| ROCE | -2024.7% | -2024.7% | -857.7% | -422.0% | -161.2% | -97.2% | -366.3% | -134.5% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.03 | — | 0.04 | 0.20 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | -1.28 | — | -0.59 | -1.03 | -1.06 | -0.97 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | -31.83 | -17.56 | -821.20 | -2.50 | — | -244.40 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.31 | 0.31 | 2.21 | 0.84 | 4.28 | 19.12 | 6.08 | 24.68 |
| Quick Ratio | 0.31 | 0.31 | 2.21 | 0.84 | 4.28 | 19.41 | 6.08 | 24.68 |
| Cash Ratio | 0.07 | 0.07 | 1.70 | 0.76 | 4.11 | 18.53 | 5.83 | 24.19 |
| Asset Turnover | — | — | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $25M | $19M | $14M | $12M | $11M | $6M | $5M |
Imminent liquidity and dilution
As reported in recent financial statements, NeuroSense's ROA has consistently remained in negative territory, reaching -139.8% in 2025Q2, which highlights the company's inability to generate returns on invested capital while it remains in a pre-revenue, high-burn clinical development phase for its lead candidate, PrimeC.
The persistent negative return on assets suggests that the company is consuming capital at a rate that far outpaces any potential value creation from its R&D pipeline. Investors should monitor whether future clinical milestones can reverse this trend, as the current trajectory indicates a rapid depletion of shareholder value.
Based on the latest quarterly filings, the company's current ratio has plummeted to 0.71 as of 2025Q2, a significant decline from historical levels that underscores the firm's inability to cover its short-term liabilities without immediate and potentially dilutive external financing.
A current ratio below 1.0 is particularly concerning for a clinical-stage biotech, as it suggests that current assets are insufficient to meet upcoming operational obligations. This liquidity profile warrants further investigation into the company's ability to maintain its going-concern status without immediate capital injections.
When compared to peers like Prothena and AC Immune, NeuroSense's financial profile appears structurally weaker, as evidenced by its extremely low cash reserves and lack of commercial revenue, which forces the market to apply a significant liquidity discount to its valuation relative to the broader sector.
The gap between NeuroSense and its peers is not merely temporary but appears structural, driven by the company's specific stage of development and its precarious cash position. Investors should interpret this discount as a reflection of the heightened execution and financing risks inherent in the firm's current business model.
The most commonly misapplied metric for NeuroSense is the Price-to-Earnings ratio, which, as shown in recent filings, is fundamentally irrelevant for a pre-revenue biotech firm and obscures the true risk profile by suggesting a valuation based on non-existent earnings rather than clinical probability of success.
Using P/E ratios for a company with no revenue and negative margins provides no insight into the firm's intrinsic value or its potential for future commercialization. Analysts should instead focus on metrics like cash runway, probability-adjusted net present value of the pipeline, and the cost of capital required to reach the next value-inflection point.
Includes 30+ ratios · 7 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying NRSN stock.
NeuroSense Therapeutics Ltd.'s current P/E ratio is -1.6x. This places it at the 50th percentile of its historical range.
NeuroSense Therapeutics Ltd.'s return on equity (ROE) is -2175.0%. The historical average is -186.2%.
Based on historical data, NeuroSense Therapeutics Ltd. is trading at a P/E of -1.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.